Ryu · Journal of cellular and molecular medicine 2009 · Post-mortem human tissue comparative analysis and controlled animal experiment · n=?

A leaky blood-brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer's disease brain.

Cited 408 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Bench and animal research (human post-mortem tissue analysis and rodent injection models)

PubMed 18657226 · doi:10.1111/j.1582-4934.2008.00434.x · record verified 2026-08-30

What was done

Researchers examined post-mortem brain tissue from Alzheimer's disease (AD) patients and non-demented controls using immunohistochemistry for fibrinogen, IgG, von Willebrand factor, and microglial markers. In parallel, rats received intra-hippocampal injections of amyloid-beta (Abeta(1-42)) alone or combined with fibrinogen over 1 to 7 days. Two interventions were tested in the animal model: the defibrinogenating agent ancrod and an anti-Mac-1 (CD11b) antibody to inhibit microglial activation.

What was found

AD brain tissue showed diffuse fibrinogen and IgG extravasation associated with Abeta deposits, altered blood vessel morphology, and microglial reactivity, which were absent in non-demented controls. In rats, Abeta(1-42) injection caused time-dependent increases in fibrinogen accumulation and microgliosis. Co-injection of Abeta(1-42) and fibrinogen produced significantly greater inflammatory reactivity, vascular perturbations, and neuronal damage than Abeta(1-42) alone. Both ancrod and anti-Mac-1 reduced inflammatory responses and provided neuroprotection. The abstract reports qualitative comparative directions without numerical values or exact statistics.

Why it matters

This study links blood-brain barrier breakdown directly to neurodegeneration in AD, demonstrating that extravasated fibrinogen amplifies amyloid-driven microglial toxicity. It highlights vascular integrity and microglial CD11b signaling as potential targets for neuroprotective interventions.

Limits

The abstract provides no sample sizes for human brain specimens or animal cohorts, nor does it report numerical effect sizes or confidence intervals. The acute intra-hippocampal peptide injection in rodents does not fully capture the chronic, progressive pathology of human Alzheimer's disease.

Cited by